Journals / Turkish Journal of Hematology / 2002 / Cilt: 19 - Sayı: 1

Does von Willebrand factor have an effect on the occurrence of the diabetic complications?

Pages
31–37
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We conclude that, vWf has not an effect in the development of complications in patients with diabetes mellitus.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It has been reported that von Willebrand factor (vWf) plays a role in the development of complications of diabetes mellitus.
📊
Key Findings & Data:The relationships between vWf and polyneuropathy, nephropathy, and retinopathy were investigated in the patients with type 2 diabetes mellitus. 58 patients with type 2 diabetes mellitus (22 men and 36 women, mean age 54 ± 9 ) and 30 healthy nondiabetic controls (12 men and 18 women, mean age 40 ± 11) were admitted to this study.
💡
Conclusion & Impact:We conclude that, vWf has not an effect in the development of complications in patients with diabetes mellitus.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:von Willebrand faktör · Polinöropatiler · Diabetik nefropati

Özet

It has been reported that von Willebrand factor (vWf) plays a role in the development of complications of diabetes mellitus. The relationships between vWf and polyneuropathy, nephropathy, and retinopathy were investigated in the patients with type 2 diabetes mellitus. 58 patients with type 2 diabetes mellitus (22 men and 36 women, mean age 54 ± 9 ) and 30 healthy nondiabetic controls (12 men and 18 women, mean age 40 ± 11) were admitted to this study. They were examined by an internist, a neurologist and an ophthalmologist for complications of diabetes mellitus. Electromyography was performed to all the patients. The mean vWf levels of the patients and control group were 1.48 ± 0.55 and 1.25 ± 0.32 IU/mL respectively. There was no significant difference between the two groups (p= 0.146). Diabetic retinopathy in 18 patients (31%), polyneuropathy in 20 patients (34.5%), trap neuropathy in 5 patients (8.6%), microalbuminuria in 9 patients (15.5%), macroalbuminuria in 2 patients (3.5%) and normoalbuminuria in 47 patients (81%) were detected. The difference between vWf levels of the patients with retinopathy and without retinopathy were not statistically significant (p= 0.913). There was no significant difference between patients with polyneuropathy and without polyneuropathy group (p= 0.737). There was also no difference between trap neuropathy and without trap neuropathy (p= 0.431), and between polyneuropathy and trap neuropathy (p= 0.246) patient subgroups. The vWf levels in normoalbuminuric, microalbuminuric and macroalbuminuric patient groups were not different (p values: 0.526, 0.392 and 0.759 respectively). vWf levels between patients with complications of diabetes mellitus and control group were not different (p> 0.05). There was not a significant correlation between the vWf level and body mass index, serum glucose, triglycerides, total cholesterol, HDL-C, LDL-C, VLDL-C, platelet counts, fibrinogen levels, prothrombin and activated thromboplastin times in 33 patients with any complication of diabetes mellitus (p> 0.05). We conclude that, vWf has not an effect in the development of complications in patients with diabetes mellitus.

🔖

Cite This Article

KADIKÖYLÜ, G., BOLAMAN, A. Z., SÖNMEZ, H. M., ÖGE, A., GÜNEY, E., AKYOL, A., DÜNDAR, S., ŞENTÜRK, T. (2002). Does von Willebrand factor have an effect on the occurrence of the diabetic complications?. Turkish Journal of Hematology, Cilt: 19 - Sayı: 1, 31–37. https://ajindex.com/articles/412983

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Nathan DM. Long term complications of diabetes mellitus. N Eng! J Med 1993;32S:1676-S5
  2. Ratner RE. Type 2 diabetes mellitus: The grand overview. Diabetic Med 1998;15:54-7
  3. Lip GY, Blann A. von Willebrand factor: A marker of endothelial dysfunction in vascular disorders? Cardi-ovasc Res 1997;34:255-65
  4. Vischer UM, Emeis JJ, Bilo HJ, Stehouwer CD, Thomsen C, Rasmussen O, Hermansen K, Wollheim CB, Ingerslev J. von Willebrand factor as a plasma marker of endotheüal activation in diabetes: Improved reliability with parallel determination of the vWf propeptide. Thrornb Haemost 199S;80:1002-7
  5. Kessler L, Wiesel ML, Attali P, Mossard JM, Cazena-ve JP, Pinget M. von Willebrand factor in diabetic angiopathy. Diabetes Metab 1998;24:327-36
  6. Paton RC, Passa P, Canivet J. von Willebrand factor, diabetes mellitus and retinopathy. Horrn Metab Res 19Sl;ll(SuppI):55-8
  7. Porta M, La Selva M, Molinatti PA. von Willebrand factor and endothelial abnormalities in diabetic mic-roangiopathy. Diabetes Care 1991;14:167-72
  8. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:llS3-97
  9. Vinikka L. Platelet function and thrombus in diabetes. Acta Endocrinol 19S5;272(Suppl):31-4
  10. Jensen T. Pathogenesis of diabetic vascular disease: Evidence for the role of reduced heparan sulfate pro-teoglycan. Diabetes 1997;46(Suppl 2):9S-100
  11. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, Wu KK. Associations of factor VIII and von Willebrand factor with age, race sex and risk factors for atherosclerosis. The atherosclerosis risk in communities (ARIC) study. Thrombosis and Ha-emostasis 1993;70:380-5
  12. Jeger A, Van Hinsberg VWM, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bo-uter LM, Stehouwer CDA. von Willebrand factor, C-reactive protein and 5-year mortality in diabetic and nondiabetic subjects: The hoorn study. Arleriosder Thromb Vase Biol 1999;19:3071-8
  13. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor, tissue plasminogen activator and dehydroepi-androsterone sulphate predict cardiovascular death in a 10 year follow up of survivors of rnyocardial infarction. Heart 199S;S0:334-7
  14. Fujiwara Y, Tagami S, Kawakami Y. Circulating thrombomodulin and hernatological alterations in type 2 diabetic patients with retinopathy. J Athe-roscler Thromb 1998;5:2l-S
  15. Neri S, Bruno CM, Leotta C, D'Amico RA, Pennisi G, lerna D. Early endothelial alterations in noninsu-li